Here is a detailed article about the news from PR Newswire, presented in a polite and informative tone:
CorestemChemon Broadens Global Clinical Research Footprint with Strategic Alliance with ATG Lifetech, Enhancing Preclinical Service Capabilities
[City, State] – July 21, 2025 – CorestemChemon, a prominent player in the global clinical research organization (CRO) landscape, is pleased to announce a significant expansion of its international reach and service offerings through a strategic partnership with ATG Lifetech. This collaboration is poised to enhance CorestemChemon’s ability to deliver next-generation preclinical services, further strengthening its commitment to advancing drug development for its diverse clientele.
The alliance with ATG Lifetech, a respected entity in the life sciences sector, marks a pivotal moment for CorestemChemon. It signifies a shared vision to provide comprehensive and cutting-edge preclinical solutions that meet the evolving demands of the pharmaceutical and biotechnology industries. By integrating ATG Lifetech’s specialized expertise and advanced technological capabilities, CorestemChemon aims to offer a more robust and sophisticated suite of preclinical services.
This strategic move is expected to benefit clients by providing access to a wider array of specialized preclinical research capabilities. These may include, but are not limited to, advanced toxicology studies, efficacy models, and bioanalytical services, all conducted with the highest scientific rigor and adherence to global regulatory standards. The synergy between CorestemChemon and ATG Lifetech is designed to streamline the preclinical phase of drug development, ultimately accelerating the journey of novel therapeutics from discovery to the clinic.
“We are delighted to welcome ATG Lifetech into our expanding global network,” stated a spokesperson for CorestemChemon. “This partnership is a testament to our dedication to innovation and our commitment to providing our clients with unparalleled support throughout the drug development process. ATG Lifetech’s reputation for excellence in preclinical research perfectly complements our own strengths, and together, we are well-positioned to address the complex challenges faced by our partners in bringing life-changing medicines to patients.”
The expansion into next-generation preclinical services underscores CorestemChemon’s proactive approach to staying at the forefront of scientific advancements. The company is focused on leveraging emerging technologies and methodologies to deliver more predictive and informative preclinical data, thereby reducing the risks and timelines associated with early-stage drug discovery and development.
This strategic alliance represents a significant step forward for CorestemChemon as it continues to solidify its position as a leading global CRO. The integration of ATG Lifetech’s capabilities is anticipated to unlock new opportunities for growth and innovation, further reinforcing CorestemChemon’s ability to serve the global pharmaceutical and biotechnology sectors with distinction. Clients can look forward to enhanced service offerings and a strengthened partnership as CorestemChemon and ATG Lifetech embark on this collaborative journey.
CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services’ at 2025-07-21 02:54. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.